DOCSLIB.ORG

Controversies in Women's Health 2016: Recognition and Treatment of Common Disorders of the Skin Disclosures a Preview Acne

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Controversies in Women's Health 2016: Recognition and Treatment of Common Disorders of the Skin Disclosures a Preview Acne Disclosures" Controversies in women’s health 2016: Recognition and treatment of common disorders I have no conflicts of interest to disclose." of the skin" " I may discuss off-label use of treatments for cutaneous disease." Kanade Shinkai, MD PhD! Associate Professor of Clinical Dermatology! University of California, San Francisco" A preview" • Fictional patient" " Acne" • Series of dermatology visits" " • Numerous concerns" "• Acne" "• Drug eruptions" "• Skin cancer" Acne “emergency”" Acne pearls for adult female patients" • Many adult females fail standard acne therapy" "- 82% fail multiple systemic antibiotics" "- 1/3 fail systemic isotretinoin" "" • Systemic antibiotics (short-term use only)" "- indicated for nodulocystic acne, truncal acne" "- may require 3 months for truncal lesions" "- works faster than hormonal therapy (2-3 weeks)" Hormonal treatment can be highly-effective for acne in this population" Hormonal therapy versus antibiotics" How do OCPs work?" • Estrogen provides the most benefit" " • Actions:" "1. Stimulates SHBG synthesis (liver): " " "- decrease free testosterone, DHEA-S" "2. Inhibit 5α-reductase" • 226 publications, 32 RCT" "3. Decrease production of ovarian, adrenal androgens" • Antibiotics superior @ 3 months" " • Equivalent to systemic antibiotics @ 6 months" • Lesion count reduction: 40-70%" " " " " " Koo EB et al (2014) JAAD 71:450-459" Koo EB et al (2014) JAAD 71:450-459" Haider A and JC Shaw (2004) JAMA 292:726-735" My acne patient didn’t respond to OCP. ! Which OCP is best?" Will adding spironolactone help?" • FDA-approved for acne: no superiority data" "-Ortho Tri-Cyclen: norgestimate + ethinyl estradiol/ EE" Effective: non-FDA approved, no placebo-controlled trials" " " "-EstroStep: norethindrone acetate + EE "" • spironolactone alone or with OCP (50-200mg/day)" " " "-Yaz: drospirenone + EE" • 33-85% reduction in acne" " " "- dosing 50-100mg/day: 33% improvement" "• High estrogen, low androgenic (progesterone) activity" " "- 100mg + drospirenone: 85% improvement" "-norgestimate, desogestrel (3rd gen progestins)" " " "-drosperinone (4th gen progestin)" " "-nomegestrel acetate (NOMAC)" Brown J et al (2009) Cochrane Database of Sys Rev 2:CD000194" Haider A and JC Shaw (2004) JAMA 292:726-735" Arowojolu AO et al (2012) Cochrane Database Syst Rev, 6:CD004425" Shaw JC (2000) JAAD 43:498-502" Haider A and JC Shaw (2004) JAMA 292:726-735" Krunic A et al (2008) JAAD 58:60-2" Spironolactone: safe, has side effects" Spironolactone: the scare over potassium" • 8 year safety study in acne: no serious complications" • Main side effects: "menstrual irregularities (22%) " " ""breast tenderness (17%) " " ""fatigue (15%) " " ""headache (13%)" • monotherapy only at low doses, select patients" • hyperkalemia (minimal rise in K+ in 13%, no sequelae) " 425 mg" 366 mg" 600 mg" 30 mg" 235 mg" • blood pressure reduction: mean 5mmHg SBP, 2.6mmHg DBP" " " " " " • TERATOGEN: Category C/D" " " RDA K+: 4700" mg" " " • Black box warning: benign tumors in animal studies" Low usefulness of screening in healthy " Haider A and JC Shaw (2004) JAMA 292:726-735 " "" young acne patients" Shaw JC (2000) JAAD 43:498-502" " Shaw JC, White LE (2002) J Cut Med Surg 6:541-545 "" " George R et al (2008) Sem Cut Med Surg 28:188-196" Plovanich M et al (2015) JAMA Derm, 151:941-944" " " " " " Do other forms of contraception help acne?" When should I worry about a hormonal disorder?" Vaginal ring: minimal data on efficacy with acne" • Hirsutism, acanthosis nigricans" "• etonorgestrel (derivative of 3rd gen progestin)" " "• Cochrane review (2010): Nuva-users have less acne" • Oligomenorrhea (<8 per year) or amenorrhea" "• adverse effects: intermediate clotting risk" " " • Virilization: "Deepening voice" Intrauterine" devices: caution" " " "Clitoromegaly" "• levonorgestrel (2nd gen progestin)" " " "Increased muscle mass" "• hormone-eluting IUDs may worsen acne (Cutis 2008)" " " "Decreased breast size" "• plasma concentration @ 1 month: 50% of Norplant" " " """"" " Virilization"" = sign of androgen-secreting tumor" " " Ilse JR et al (2008) Cutis, 82: 158" Azziz R et al (2004) J Clin Endo Metab, 89:453-462" Lopez LM et al (2010) Cochrane Review, CD003552" " Escobar-Morreale H et al (2012) Hum Reprod Update, 18:146-170" Chi IC (1991) Contraception, 44: 573--588" JC Harper (2008) J Drugs Derm 7: 527-530" Lolis MS et al (2009) Med Clin N Am 93:1161-1181 "" " " " Hyperandrogenism workup: results" Polycystic Ovary Syndrome (PCOS)" Rotterdam criteria (2003): 2 of 3" PCOS Idiopathic Idiopathic NCCAH Tumors Misc "• oligomenorrhea (< 8 per year)" HA Hirsutism "• serum or clinical hyperandrogenism" "• ultrasound (+) polycystic ovaries" 71% 15% 10% 3% 0.3% 0.7% • Prevalence: 5-10%" • Heterogeneous presentation" " PCOS is #1 cause of androgen excess" Tumors, hormonal disorders are very rare" " " Escobar-Morreale H et al (2012) Human Repro Update, 18:146-170" Stein & Leventhal (1935) Am J Obstet Gynecol, 29:181-191 "" Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004) Human Reproduc. 19:41-47 "" " Cutaneous signs of PCOS" Hirsutism: best skin sign of hyperandrogenism" Pearls:" • look beyond the face (trunk, proximal extremities)" " • spironolactone 100 qD- BID has best efficacy" Cross-sectional UCSF study" 401 women suspected of having PCOS " Comprehensive skin exam by dermatologist" 92% of patients with PCOS had skin finding "" Schmidt T et al (2015) JAMA Derm, Dec 23:1-8! " Schmidt TH, Shinkai K (2015) JAAD 73:672-690" " " Androgenic alopecia: poor skin sign of Diagnostic workup for PCOS" hyperandrogenism" Step 1:" Step 2:" When? Endocrine" Metabolic" Pearls:" " " • Testosterone (free, total)" • BMI" • frontal hairline is " " preserved" • 17-hydroxyprogesterone" • Blood pressure" • total baldness is rare in • trans-vaginal ultrasound" • Fasting lipid panel" women" " • Fasting insulin, glucose" " •" DHEA-S" • 2 hour glucose challenge" • topical minoxidil 5% daily" "• TSH" • HgbA1c" • 6-12 months" • prolactin" • ALT" • androstenedione! " • LH: FSH (>3 in 95% PCOS)! " Dizon M, Schmidt TH, Shinkai K (2016) Cutis, 98:11-13" Schmidt TH, Shinkai K (2015) JAAD 73:672-690" " " " " Back to our acne patient:! Drug eruptions" 10 days after starting doxycycline, your patient develops an itchy generalized maculopapular rash" Morbilliform drug eruption" • common" • erythematous macules, papules " (can be confluent)" • pruritus" • no systemic symptoms " • begins in 1st or 2nd week" • treatment: " "-D/C med if severe" "-symptomatic treatment: " " hydroxyzine, topical steroids" " When do the symptoms subside? " Drug eruptions: ! Up to 1 week" when to worry" Minimal systemic symptoms" Systemic involvement" Morbilliform drug eruption" DRESS" " AGEP" " Stevens-Johnson (SJS)" " Toxic epidermal necrolysis" " (TEN)" Simple" Complex" Potentially life threatening" Require systemic immunosuppression" Drug eruptions: ! Signs of a serious drug eruption:" timing of onset can be helpful" • Mucosal involvement (ie, oral ulcerations)" Minimal systemic symptoms" Systemic involvement" • Erythroderma" • Skin pain" Morbilliform drug eruption" DRESS" 2-6 weeks" • Target lesions" 5-14" days" AGEP" 1-4 days" • Bullous lesions" " Stevens-Johnson (SJS)" • Denudation (skin falling off in sheets)" " Toxic epidermal necrolysis" • Pustules" " (TEN) "5-20 days" • Facial swelling, anasarca" Simple" Complex" • Fever" • Internal organ involvement: liver, kidney > lung, cardiac" Potentially life threatening" Require systemic immunosuppression" Target lesions: Stevens Johnson Syndrome (SJS)" Mucosal involvement: SJS/ TEN" Facial swelling: drug-induced hypersensitivity Bullous lesions, denudation, pain: TEN" syndrome or DRESS! Also: eosinophilia, transaminitis, renal failure" Widespread pustules: acute generalized Drug eruption pearls" exanthematous pustulosis (AGEP)! Also: eosinophilia, renal failure" Look for cutaneous signs of a potentially-fatal drug eruption" " Consider ordering labs if you are not sure " "" " Lab order! What you are looking for! Drug eruption! CBC with differential" Eosinophilia" Any drug hypersensitivity" (may be slightly increased in simple drug eruption)" ALT, AST" Transaminitis" Drug-induced hypersensitivity syndrome" BUN, Cr" Acute renal failure" Drug-induced hypersensitivity syndrome, AGEP" Patient returns with a changing mole" “Spots,” skin cancers, melanoma" Melanoma" Melanoma" A " = "asymmetry" " B = "irregular border" " C" = "color" " D" = "diameter >6mm" " E " = "evolution" " complete biopsy" " Melanoma: initial evaluation" D/dx of a pigmented lesion?" •$ Prognosis is DEPENDENT on the depth of Mole/ nevus" lesion (Breslow’s depth)" " –$< 1mm thickness is low risk" –$> 1mm consider sentinel lymph node biopsy" •$ If melanoma is on the differential, complete excision or full thickness incisional biopsy is indicated" Seborrheic keratoses" Seborrheic keratoses" • benign keratinocytic papules" " • trunk, extremities > face" " • do not progress to malignancy" " • stuck-on tan, ovoid papule/ plaque" " • sometimes symptomatic" " Solar lentigo/lentigines" Cherry angioma (d/dx: Spitz nevus, melanoma)" Pigmented, flat, even color" Irregular borders" Multiple, 1-2 mm in size" Sun exposed areas" Age 30+" " " Actinic purpura, actinic keratoses" Non-melanoma skin cancer" What about this new skin lesion?" Basal cell carcinoma" • pearly papule or plaque " " - central ulceration" " - telangiectasia" " • slow growing" " • invade locally" " • Rx: surgical excision" " "curettage" " "superficial -> topical" BCC can be pigmented" Squamous cell carcinoma" • scaly erythematous plaque
Load more

Recommended publications
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Progestogens and Venous Thromboembolism Among Postmenopausal Women Using Hormone Therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin
    Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin To cite this version: Marianne Canonico, Geneviève Plu-Bureau, Pierre-Yves Scarabin. Progestogens and venous throm- boembolism among postmenopausal women using hormone therapy.. Maturitas, Elsevier, 2011, 70 (4), pp.354-60. 10.1016/j.maturitas.2011.10.002. inserm-01148705 HAL Id: inserm-01148705 https://www.hal.inserm.fr/inserm-01148705 Submitted on 5 May 2015 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Progestogens and VTE Finale version Progestogens and venous thromboembolism among postmenopausal women using hormone therapy Marianne Canonico1,2, Geneviève Plu-Bureau1,3 and Pierre-Yves Scarabin1,2 1 Centre for Research in Epidemiology and Population Health, U1018, Hormones and Cardiovascular Disease 2 University Paris-Sud, UMR-S 1018, Villejuif, France 3 University Paris Descartes and Hôtel-Dieu Hospital, Paris, France Adresse: 16 av. Paul Vaillant Couturier 94807 Villejuif Cedex Tel: +33 1 45 59 51 66 Fax: +33 1 45 59 51 70 Corresponding author: Marianne Canonico ([email protected]) 1/21 Progestogens and VTE Finale version Abstract Hormone therapy (HT) is the most effective treatment for correcting menopausal symptoms after menopause.
    [Show full text]
  • Steroid Abuse by School Age Children
    epartment .D of .S Ju U s t ic U.S. Department of Justice e . n o i Drug Enforcement Administration t a r t is D in Office of Diversion Control r m ug d E t A nforcemen www.dea.gov www.DEAdiversion.usdoj.gov epartment .D of .S Ju U s t ic e . n o i t a r t is D in r m ug d E t A nforcemen Office of Diversion Control www.dea.gov STEROID ABUSE BY SCHOOL AGE CHILDREN nce viewed as a problem strictly associated with body builders, Ofitness “buffs,” and professional athletes, abuse of anabolic steroids by school age children has significantly increased over the past decade. The National Institute on Drug Abuse (NIDA) estimates that more than a half million 8th and 10th grade students are now using these dangerous drugs, and increasing numbers of high school seniors do not believe steroids are risky. Students are acquiring and taking anabolic steroids without any knowledge of the dangers associated with steroid abuse. The short- term adverse physical effects of anabolic steroid abuse are fairly well known. However, the long-term adverse physical effects of anabolic steroid abuse have not been studied, and as such, are not known. In addition, this type of abuse may result in harmful side-effects as well as serious injury and death. The abuser in most cases is unaware of these hidden dangers. Presented as a public service by: This guide will help you understand why steroids are being misused, Drug Enforcement Administration and how you can provide counseling and implement procedures to Office of Diversion Control educate our youth about the dangers of these drugs.
    [Show full text]
  • Role of Androgens, Progestins and Tibolone in the Treatment of Menopausal Symptoms: a Review of the Clinical Evidence
    REVIEW Role of androgens, progestins and tibolone in the treatment of menopausal symptoms: a review of the clinical evidence Maria Garefalakis Abstract: Estrogen-containing hormone therapy (HT) is the most widely prescribed and well- Martha Hickey established treatment for menopausal symptoms. High quality evidence confi rms that estrogen effectively treats hot fl ushes, night sweats and vaginal dryness. Progestins are combined with School of Women’s and Infants’ Health The University of Western Australia, estrogen to prevent endometrial hyperplasia and are sometimes used alone for hot fl ushes, King Edward Memorial Hospital, but are less effective than estrogen for this purpose. Data are confl icting regarding the role of Subiaco, Western Australia, Australia androgens for improving libido and well-being. The synthetic steroid tibolone is widely used in Europe and Australasia and effectively treats hot fl ushes and vaginal dryness. Tibolone may improve libido more effectively than estrogen containing HT in some women. We summarize the data from studies addressing the effi cacy, benefi ts, and risks of androgens, progestins and tibolone in the treatment of menopausal symptoms. Keywords: androgens, testosterone, progestins, tibolone, menopause, therapeutic Introduction Therapeutic estrogens include conjugated equine estrogens, synthetically derived piperazine estrone sulphate, estriol, dienoestrol, micronized estradiol and estradiol valerate. Estradiol may also be given transdermally as a patch or gel, as a slow release percutaneous implant, and more recently as an intranasal spray. Intravaginal estrogens include topical estradiol in the form of a ring or pessary, estriol in pessary or cream form, dienoestrol and conjugated estrogens in the form of creams. In some countries there is increasing prescribing of a combination of estradiol, estrone, and estriol as buccal lozenges or ‘troches’, which are formulated by private compounding pharmacists.
    [Show full text]
  • The Combined Cardiac Effect of the Anabolic Steroid, Nandrolone And
    ù1. v -¿. rlc) 77.- *n*hi.rnool oowol,ù*o ffi"/fu -lo *rn*(o fii'o fio¿o¿¿, /v&"ùún lonno **al cooaiæe';¿vfl"- oã. Benjamin D. Phillis, B.Sc. (Hons) Phatmacology Depattment of Clinical & Experimental Pharmacology Ftome Rd. , Medical School Noth Adelaide Univetsity ADEIAIDE SA 5OOO û.)r.'-*hr/7enveltîù Foremost, I would like to thank my two supervisors for the direction that they have given this ptojecr. To Rod, for his unfailing troubleshooting abiJity and to Jenny fot her advice and ability to add scientific rigour' Many thanks to Michael Adams for his technical assistance and especially fot performing the surgery for the ischaemia-reperfusion projects and for his willingness to work late nights and public holidays. Lastly I would like to thank my v¡ife for her extreme patience during the tumult of the last 5 years. Her love, suppoït, patience and undetstanding have been invaluable in this endeavout. Beniamin D. Phillis Octobet,2005 ADE,I-AIDE ii T*(¿t of Ao,t",tù DECI.ARATION I ACKNOWLEDGEMENTS il TABLE OF CONTENTS UI ABBREVIATIONS x ABSTRACT )ilr CÉIAPTER t-l Inttoduction 1-1 1.1 Background 1,-1, 1.2What ate anabolic stetoids? 7-1 1,3 General pharmacology of Anabolic steroids t-2 '1,-2 1.3.1 Genomic effects of anabolic steroids 1.3.2 Non-genomic effects of anabolic steroids 1-3 1.4 Clinical use of AS 1.-4 1.5 Patterns of AS abuse 1.-4 1.5.1 Steroid abuse by athletes 1.-+ 1.5.2 Stetoid abuse by sedentary teenagers r-6 1.5.3 Prevalence of abuse 1-6 1.5.4 Abuse ptevalence in Australia 1.-9 1.6 Cardiotoxicity of anabolic steroids r-9 1.6.1 Reduced cotonary flow 1.-1.1, 1,.6.2 Dtect myocatdial eff ects 1-1 5 1.6.3 Hypertension 1-21 1.7 Difficulties associated with anabolic steroid research 1.-24 1-25 1.8 The polydrug abuse Phenomenon 1.9 The pharmacology of cocaine 1-26 1.10 Pteparations 1-28 1-29 1.11 Metabolism lll 1-30 1.
    [Show full text]
  • Spironolactone for Adult Female Acne
    ® PPracticalEDIATRIC DERMATOLOGY Pearls From the Cutis Board Spironolactone for Adult Female Acne Many cases of acne are hormonal in nature, meaning that they occur in adolescent girls and women and are aggravated by hormonal fluctuations such as those that occur during the menstrual cycle or in the setting of underlying hormonal imbalances as seen in polycystic ovary syndrome. For these patients, antihormonal therapy such as spironolactone is a valid and efficacious option. Herein, initiation and utilization of this medication is reviewed. Adam J. Friedman, MD copy What should you do during the first Evaluation of these women with acne for the visit for a patient you may start possibility of hormonal imbalance may be necessary, on spironolactone? with the 2 most common causes of hyperandrogen- Some women will come in asking about spironolac- ismnot being polycystic ovary syndrome and congeni- tone for acne, so it is important to identify potential tal adrenal hyperplasia. The presence of alopecia, candidates for antihormonal therapy: hirsutism, acanthosis nigricans, or other signs of • Women with acne flares that cycle androgen excess, in combination with dysmenor- with menstruation Dorhea or amenorrhea, may be an indication that the • Women with adult-onset acne or persistent- patient has an underlying medical condition that recurrent acne past teenaged years, even needs to be addressed. Blood tests including testos- in the absence of clinical or laboratory signs terone, dehydroepiandrosterone, follicle-stimulating of hyperandrogenism hormone, and luteinizing hormone would be appro- • Women on oral contraceptives (OCs) who priate screening tests and should be performed dur- exhibit moderate to severe acne, especially ing the menstrual period or week prior; the patient with a hormonal patternCUTIS clinically should not be on an OC or have been on one within • Women not responding to conventional ther- the last 6 weeks of testing.
    [Show full text]
  • The Realization of New Medical Alternatives to Surgery for Endometriosis
    Paradigm Shift: The Realization of New Medical Alternatives to Surgery for Endometriosis Edward M. Lichten, MD* ©2016, Edward M. Lichten, MD Journal Compilation ©2016, AARM DOI 10.14200/jrm.2016.5.0099 ABSTRACT Endometriosis is one of the most destructive benign diseases of women. It is established as developing and being present in upward of 70% of adolescents who do not experience relief of menstrual pain with use of oral contraceptives and anti- inflammatory drugs. It occurs in 8%–10% of women in the United States and is most prevalent in developed countries. Symptoms of endometriosis include disabling pain, hemorrhagic uterine bleeding, and infertility. Women with disease can expect a 12% hysterectomy rate. While present medical therapy may offer relief of many symptoms, there have been no major new directions in pharmacologic therapy since leuprolide acetate was made available in 1977. Danazol remains the only alternative to GnRH agonists with proven efficacy and reasonable side effects, according to Cochrane Reviews, yet, it is underused, and GnRH agonists are favored even when Danazol in combination seems more effective. A previously published case report on use of the combination of nandrolone and stanozolol to treat a young woman scheduled for hemicolectomy is discussed as an alternative to surgery along with the limits of standard therapy. This review will focus on recent research and theories seeking to establish causation for disease and offer treatment recommendations. Keywords: Endometriosis; Environmental toxins; Xenoestrogens;
    [Show full text]
  • Honey, Not Tonight; I Have a Headache
    FEMALE SEXUAL DYSFUNCTION: HOPE AND HELP FOR YOUR PATIENTS Kris Christiansen, MD Park Nicollet Sexual Medicine and Male Infertility St. Louis Park, MN March 28, 2019 DISCLOSURES • I have no financial disclosures to discuss. • Off-label use of medications will be discussed in this presentation. • The use of medications for conditions not approved by the FDA can be used by clinicians according to their discretion but needs to be disclosed to patients at the time of prescribing. OBJECTIVES • Discuss effective examples of how to take a sexual history • Review common female sexual dysfunctions • Learn about treatment options for female sexual problems 94% of U.S. adults feel sexual pleasure adds to quality of life • Brunk, Family Practice News & Internal Medicine News 5/10/2013. • C. Marwick, “Survey says patients expect little physician help on sex. • Laumann, A. Paik JAMA 1999; 281. PRINCIPLES FOR SEXUAL HISTORY TAKING • Patients prefer that health care provider initiate topic and advise (90%) • Use simple, direct language • Compassion, honesty, normalizing statements • Declare and demonstrate lack of embarrassment • Be aware of patient’s cultural background • Ensure confidentiality • Avoid judgement and assumptions Athanasiadis L, Papaharitou S, Salpiggidis G et al. J Sex Med 2006;3(1):47-55. Sadovsky R, Nusbaum M. J Sex Med. 2006;3(1);3-11. HOW TO CONDUCT THE INTERVIEW • Use words and body language that put the patient at ease • Open, non-defensive body posture • Sit and maintain eye contact • Avoid nervous gestures • Choose language appropriate to age, ethnicity, and culture of patients • Practice using sexual terminology • Ask open-ended questions • Use silences to allow patients to speak Athanasiadis L, Papaharitou S, Salpiggidis G et al.
    [Show full text]
  • Aldactone® Spironolactone Tablets, USP
    NDA 12-151/S-062 Page 2 Aldactone® spironolactone tablets, USP WARNING Aldactone has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions). Aldactone should be used only in those conditions described under Indications and Usage. Unnecessary use of this drug should be avoided. DESCRIPTION Aldactone oral tablets contain 25 mg, 50 mg, or 100 mg of the aldosterone antagonist spironolactone, 17-hydroxy-7α-mercapto-3-oxo-17α-pregn-4-ene-21-carboxylic acid γ-lactone acetate, which has the following structural formula: Spironolactone is practically insoluble in water, soluble in alcohol, and freely soluble in benzene and in chloroform. Inactive ingredients include calcium sulfate, corn starch, flavor, hypromellose, iron oxide, magnesium stearate, polyethylene glycol, povidone, and titanium dioxide. ACTIONS / CLINICAL PHARMACOLOGY Mechanism of action: Aldactone (spironolactone) is a specific pharmacologic antagonist of aldosterone, acting primarily through competitive binding of receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule. Aldactone causes increased amounts of sodium and water to be excreted, while potassium is retained. Aldactone acts both as a diuretic and as an antihypertensive drug by this mechanism. It may be given alone or with other diuretic agents which act more proximally in the renal tubule. Aldosterone antagonist activity: Increased levels of the mineralocorticoid, aldosterone, are present in primary and secondary hyperaldosteronism. Edematous states in which secondary aldosteronism is usually involved include congestive heart failure, hepatic cirrhosis, and the nephrotic syndrome. By competing with aldosterone for receptor sites, Aldactone provides effective therapy for the edema and ascites in those conditions.
    [Show full text]
  • Spironolactone 2016
    Spironolactone 2016 Alert Spironolactone is a potassium-sparing diuretic and concomitant intake of potassium or ACE inhibitors may lead to hyperkalemia. Indication Diuretic primarily prescribed for its potassium-sparing effect. For heart failure, in conjunction with furosemide. For chronic lung disease, in conjunction with a thiazide diuretic. Bartter syndrome and Gitelman Syndrome. Action Spironolactone is a synthetic steroid that acts as a competitive aldosterone receptor antagonist, so inhibits sodium reabsorption and spares potassium. It is a weak diuretic. It also inhibits the interaction between dihydrotestosterone and the intracellular androgen receptor resulting in moderate antiandrogenic activity.. Drug Type N on - selective mineralocorticoid receptor antagonist. Trade Name Aldactone; Spiractin Presentation Oral suspension prepared in pharmacy. 2.5 mg/mL; 5 mg/mL. Dosage / Interval 1 – 3 mg/kg/dose 24 hourly. Dose can be divided into different intervals. Maximum daily dose 3 mg/kg/day Route Oral Preparation/Dilution Oral suspension. Administration Administer undiluted with feeds. Monitoring Serum potassium at regular intervals. Contraindications Hyperkalaemia . Significant renal impairment. Anuria. Adrenal insufficiency. Precautions Use with caution in infants with renal or hepatic impairment. Monitor more frequently if infant is also given potassium. Drug Interactions Spironolactone increases the effects of ACE inhibitors (leading to hyperkalemia), digoxin and sotalol. Adverse Reactions Hyperkalaemia and metabolic acidosis. Antiandrogenic effects include reduced hirsutism and gynecomastia. There is one case report of an ovarian cyst in a neonate on spironolactone. Spironolactone interferes with 17-hydroxyprogesterone measurement, which is used to screen neonates for congenital adrenal hyperplasia. Reduces clearance of digoxin. Compatibility N/A Incompatibility N/A Stability Biochemical stability when stored in solution for 1 month.1 Storage Store below 25oC.
    [Show full text]
  • Appendix B - Product Name Sorted by Applicant
    JUNE 2021 - APPROVED DRUG PRODUCT LIST B - 1 APPENDIX B - PRODUCT NAME SORTED BY APPLICANT ** 3 ** 3D IMAGING DRUG * 3D IMAGING DRUG DESIGN AND DEVELOPMENT LLC AMMONIA N 13, AMMONIA N-13 FLUDEOXYGLUCOSE F18, FLUDEOXYGLUCOSE F-18 SODIUM FLUORIDE F-18, SODIUM FLUORIDE F-18 3M * 3M CO PERIDEX, CHLORHEXIDINE GLUCONATE * 3M HEALTH CARE INC AVAGARD, ALCOHOL (OTC) DURAPREP, IODINE POVACRYLEX (OTC) 3M HEALTH CARE * 3M HEALTH CARE INFECTION PREVENTION DIV SOLUPREP, CHLORHEXIDINE GLUCONATE (OTC) ** 6 ** 60 DEGREES PHARMS * 60 DEGREES PHARMACEUTICALS LLC ARAKODA, TAFENOQUINE SUCCINATE ** A ** AAA USA INC * ADVANCED ACCELERATOR APPLICATIONS USA INC LUTATHERA, LUTETIUM DOTATATE LU-177 NETSPOT, GALLIUM DOTATATE GA-68 AAIPHARMA LLC * AAIPHARMA LLC AZASAN, AZATHIOPRINE ABBVIE * ABBVIE INC ANDROGEL, TESTOSTERONE CYCLOSPORINE, CYCLOSPORINE DEPAKOTE ER, DIVALPROEX SODIUM DEPAKOTE, DIVALPROEX SODIUM GENGRAF, CYCLOSPORINE K-TAB, POTASSIUM CHLORIDE KALETRA, LOPINAVIR NIASPAN, NIACIN NIMBEX PRESERVATIVE FREE, CISATRACURIUM BESYLATE NIMBEX, CISATRACURIUM BESYLATE NORVIR, RITONAVIR SYNTHROID, LEVOTHYROXINE SODIUM ** TARKA, TRANDOLAPRIL TRICOR, FENOFIBRATE TRILIPIX, CHOLINE FENOFIBRATE ULTANE, SEVOFLURANE ZEMPLAR, PARICALCITOL ABBVIE ENDOCRINE * ABBVIE ENDOCRINE INC LUPANETA PACK, LEUPROLIDE ACETATE ABBVIE ENDOCRINE INC * ABBVIE ENDOCRINE INC LUPRON DEPOT, LEUPROLIDE ACETATE LUPRON DEPOT-PED KIT, LEUPROLIDE ACETATE ABBVIE INC * ABBVIE INC DUOPA, CARBIDOPA MAVYRET, GLECAPREVIR NORVIR, RITONAVIR ORIAHNN (COPACKAGED), ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
    [Show full text]
  • Hepatotoxicity Associated with Illicit Use of Anabolic Androgenic Steroids in Doping
    Eur opean Rev iew for Med ical and Pharmacol ogical Sci ences 2017; 21 (1 Suppl): 7-16 Hepatotoxicity associated with illicit use of anabolic androgenic steroids in doping R. SOLIMINI, M.C. ROTOLO, L. MASTROBATTISTA, C. MORTALI, A. MINUTILLO, S. PICHINI, R. PACIFICI, I. PALMI Department of Therapeutic Research and Medicines Evaluation, Drug Abuse and Doping Unit, Istituto Superiore di Sanità, Rome, Italy Abstract. – Anabolic Androgenic Steroids Since then , several synthetic analogs of testos - (AAS) abuse and misuse is nowadays a harmful terone, known as Anabolic Androgenic Steroids habit involving both professional or recreational (AAS) or designer steroids (e.g . methyltestos - athletes, as well as general population. AAS are also frequently present in over-the-counter di - terone in 1935 , nandrolone in 1950 and 1953, etary supplements without being declared in the testosterone esters from mid-1950s, stanozolol list of ingredients, leaving consumers unaware and oxymetholone in 1959 , oxandrolone in 1962) of the risks of adverse effects. Indeed, health have been produced in the attempt to minimize risks of AAS consumption in pharmaceutical the androgenic effects and improve the anabolic preparations or dietary complements seem still ones 1,2,7-9 . However , a successful complete sepa - underestimated and under-reported. The variety of complications due to AAS misuse involves ration of the anabolic and the androgenic proper - cardiovascular, central nervous, musculoskeletal ties has never been realized in the synthetic de - and genitourinary systems of both males and fe - rivatives of testosterone 1,2,10,11 . Among those, nan - males; psychiatric and behavioral effects, dam - drolone was the first compound which showed a ages to metabolic system, skin and mainly liver.
    [Show full text]